Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-043365
Filing Date
2025-05-14
Accepted
2025-05-14 16:31:13
Documents
56
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0240597-10q_estrella.htm   iXBRL 10-Q 532697
2 CERTIFICATION ea024059701ex31-1_estrella.htm EX-31.1 9361
3 CERTIFICATION ea024059701ex31-2_estrella.htm EX-31.2 9343
4 CERTIFICATION ea024059701ex32-1_estrella.htm EX-32.1 3434
5 CERTIFICATION ea024059701ex32-2_estrella.htm EX-32.2 3529
  Complete submission text file 0001213900-25-043365.txt   3841227

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE esla-20250331.xsd EX-101.SCH 37060
7 XBRL CALCULATION FILE esla-20250331_cal.xml EX-101.CAL 23193
8 XBRL DEFINITION FILE esla-20250331_def.xml EX-101.DEF 190468
9 XBRL LABEL FILE esla-20250331_lab.xml EX-101.LAB 317374
10 XBRL PRESENTATION FILE esla-20250331_pre.xml EX-101.PRE 194893
59 EXTRACTED XBRL INSTANCE DOCUMENT ea0240597-10q_estrella_htm.xml XML 331361
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40608 | Film No.: 25946298
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)